Efficacy and safety of acotiamide for the treatment of functional dyspepsia: Systematic review and meta-analysis

Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Xiao, Guoguang ^a   Xie, Xiaoping ^b   Fan, Juan ^c   Deng, Jianjun ^a   Tan, Shan ^a   Zhu, Yu ^a   Guo, Qin ^a   Wan, Chaomin ^a  

^a SICHUAN UNIVERSITY   (China)

^b Department of Stomatology   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACOTIAMIDE; ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; TRIACYLGLYCEROL; BENZAMIDE DERIVATIVE; THIAZOLE DERIVATIVE;

BILIRUBIN BLOOD LEVEL; CONSTIPATION; DIARRHEA; DISTRESS SYNDROME; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; HUMAN; LEUKOCYTE COUNT; META ANALYSIS; NCT01973790; PROLACTIN BLOOD LEVEL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; DOSE RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSPEPSIA; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES;

EID: 84907228638     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/541950     Document Type: Review

References (35)

1. Tack J., Talley N. J., Camilleri M., Holtmann G., Hu P., Malagelada J., Stanghellini V., Functional gastroduodenal disorders. Gastroenterology 2006 130 5 1466 1479 10.1053/j.gastro.2005.11.059 2-s2.0-33646178930
2. Brook R. A., Kleinman N. L., Choung R. S., Melkonian A. K., Smeeding J. E., Talley N. J., Functional dyspepsia impacts absenteeism and direct and indirect costs. Clinical Gastroenterology and Hepatology 2010 8 6 498 503 10.1016/j.cgh.2010.03.003 2-s2.0-77952743651
3. Tack J., Caenepeel P., Fischler B., Piessevaux H., Janssens J., Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001 121 3 526 535 2-s2.0-0034837093
4. Kindt S., Tack J., Impaired gastric accommodation and its role in dyspepsia. Gut 2006 55 12 1685 1691 10.1136/gut.2005.085365 2-s2.0-33845383345
5. Tack J., Piessevaux H., Coulie B., Caenepeel P., Janssens J., Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998 115 6 1346 1352 10.1016/S0016-5085(98)70012-5 2-s2.0-0031731346
6. Sarnelli G., Caenepeel P., Geypens B., Janssens J., Tack J., Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. The American Journal of Gastroenterology 2003 98 4 783 788 10.1111/j.1572-0241.2003.07389.x 2-s2.0-0012720070
7. Stanghellini V., Tosetti C., Paternico A., Barbara G., Morselli-Labate A. M., Monetti N., Marengo M., Corinaldesi R., Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996 110 4 1036 1042 10.1053/gast.1996.v110.pm8612991 2-s2.0-0029862629
8. Tack J., Prokinetics and fundic relaxants in upper functional GI disorders. Current Opinion in Pharmacology 2008 8 6 690 696 10.1016/j.coph.2008.09.009 2-s2.0-55649095491
9. Tack J., Masaoka T., Janssen P., Functional dyspepsia. Current Opinion in Gastroenterology 2011 27 6 549 557 10.1097/MOG.0b013e32834b7ca8 2-s2.0-80054700044
10. Tack J., Janssen P., Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia. Expert Opinion on Investigational Drugs 2011 20 5 701 712 10.1517/13543784.2011.562890 2-s2.0-79953668479
11. Kusunoki H., Haruma K., Manabe N., Imamura H., Kamada T., Shiotani A., Hata J., Sugioka H., Saito Y., Kato H., Tack J., Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterology and Motility 2012 24 6 540-545, e250 e251 10.1111/j.1365-2982.2012.01897.x 2-s2.0-84861185270
12. Seto K., Sasaki T., Katsunuma K., Kobayashi N., Tanaka K., Tack J., Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterology and Motility 2008 20 9 1051 1059 10.1111/j.1365-2982.2008.01135.x 2-s2.0-49749087225
13. Matsunaga Y., Tanaka T., Yoshinaga K., Ueki S., Hori Y., Eta R., Kawabata Y., Yoshii K., Yoshida K., Matsumura T., Furuta S., Takei M., Tack J., Itoh Z., Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. Journal of Pharmacology and Experimental Therapeutics 2011 336 3 791 800 10.1124/jpet.110.174847 2-s2.0-79951961277
14. Nagahama K., Matsunaga Y., Kawachi M., Ito K., Tanaka T., Hori Y., Oka H., Takei M., Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterology and Motility 2012 24 6 566 e256 10.1111/j.1365-2982.2012.01912.x 2-s2.0-84862799603
15. Adam B., Liebregts T., Zschau N. B., T1266 Z-338 improves meal-induced symptoms in functional dyspepsia: a double-blind, randomized, placebo controlled crossover study. Gastroenterology 2009 136 5, supplement 1 A-535 10.1016/S0016-5085(09)62461-6
16. Matsueda K., Hongo M., Tack J., Aoki H., Saito Y., Kato H., Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia 100 mg t.i.d. is an optimal dosage. Neurogastroenterology and Motility 2010 22 6 618 e173 10.1111/j.1365-2982.2009.01449.x 2-s2.0-77950503626
17. Tack J., Masclee A., Heading R., Berstad A., Piessevaux H., Popiela T., Vandenberghe A., Kato H., A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterology and Motility 2009 21 3 272 280 10.1111/j.1365-2982.2009.01261.x 2-s2.0-60649100914
18. Talley N., Tack J., Kowalski D., Borton M., Barve A., A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology 2008 134 supplement 1 A157 A158
19. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J. M., Gavaghan D. J., McQuay H. J., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996 17 1 1 12 10.1016/0197-2456(95)00134-4 2-s2.0-0029914622
20. Enestvedt B. K., Tofani C., Laine L. A., Tierney A., Fennerty M. B., 4-Liter split-dose polyethylene glycol is superior to other bowel preparations, based on systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2012 10 11 1225 1231 10.1016/j.cgh.2012.08.029 2-s2.0-84867678327
21. Higgins J. P. T., Thompson S. G., Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002 21 11 1539 1558 10.1002/sim.1186 2-s2.0-0037098199
22. Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G., Measuring inconsistency in meta-analyses. British Medical Journal 2003 327 7414 557 560 10.1136/bmj.327.7414.557 2-s2.0-0041876133
23. Egger M., Smith G. D., Schneider M., Minder C., Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997 315 7109 629 634 10.1136/bmj.315.7109.629 2-s2.0-0030922816
24. Matsueda K., Hongo M., Sasaki D., Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia (FD). Gastroenterology 2005 128 supplement 2, article A467
25. Matsueda K., Hongo M., Tack J., Saito Y., Kato H., A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012 61 6 821 828 10.1136/gutjnl-2011-301454 2-s2.0-84859855819
26. Camilleri M., Mangel A. W., Fehnel S. E., Drossman D. A., Mayer E. A., Talley N. J., Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clinical Gastroenterology and Hepatology 2007 5 5 534 540 10.1016/j.cgh.2007.03.004 2-s2.0-34247491532
27. Blum A. L., Talley N. J., O'Morain C., Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. The New England Journal of Medicine 1998 339 26 1875 1881
28. Tack J., Delia T., Ligozio G., Sue S., Lefkowitz M., Vandeplassche L., A phase II placebo controlled randomized trial with tegaserod in functional dyspepsia patients with normal gastoric emptying. Gastroenterology 2002 122 supplement 4, article A154
29. Van Zanten S. V., Armstrong D., Chiba N., Flook N., White R. J., Chakraborty B., Gasco A., Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. The American Journal of Gastroenterology 2006 101 9 2096 2106 10.1111/j.1572-0241.2006.00751.x 2-s2.0-33748369872
30. Vakil N., Laine L., Talley N. J., Zakko S. F., Tack J., Chey W. D., Kralstein J., Earnest D. L., Ligozio G., Cohard-Radice M., Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. American Journal of Gastroenterology 2008 103 8 1906 1919 10.1111/j.1572-0241.2008.01953.x 2-s2.0-49349102447
31. Cuomo R., Sarnelli G., Grasso R., Bruzzese D., Pumpo R., Salomone M., Nicolai E., Tack J., Budillon G., Functional dyspepsia symptoms, gastric emptying and satiety provocative test: analysis of relationships. Scandinavian Journal of Gastroenterology 2001 36 10 1030 1036 10.1080/003655201750422611 2-s2.0-0034862434
32. Simrén M., Vos R., Janssens J., Tack J., Unsuppressed postprandial phasic contractility in the proximal stomach in functional dyspepsia: relevance to symptoms. The American Journal of Gastroenterology 2003 98 10 2169 2175 10.1016/S0002-9270(03)00626-9 2-s2.0-0142183686
33. Altan E., Masaoka T., Farré R., Tack J., Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: Postprandial distress syndrome. Expert Review of Gastroenterology and Hepatology 2012 6 5 533 544 10.1586/egh.12.34 2-s2.0-84867551602
34. Matsueda K., Hongo M., Ushijima S., Akiho H., A Long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion 2011 84 4 261 268 10.1159/000332404 2-s2.0-84055200125
35. Corsetti M., Tack J., FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterology and Motility 2013 25 6 453 457 10.1111/nmo.12151 2-s2.0-84877968957